Redx Pharma Plc (LON:REDX)

Redx Pharma Plc (LON:REDX)


Share Price
5.35 p
Change
0 (0.00 %)
Market Cap
£6.77 m
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Redx ROCK2 inhibitors poster to be presented


RNS Number : 6870E
Redx Pharma plc
22 October 2018
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego

 

Alderley Park, 22 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, is pleased to announce that the Company's poster, entitled 'ROCK2 inhibitors for the treatment of chronic kidney disease' will be presented at the American Society of Nephrology (ASN) Kidney Week 2018 in San Diego, CA, on 25 October 2018 from 10:00am to 12:00pm.

 

The title, timing and location of the poster presentation is as follows:

 

Abstract Number:

3014989



Title:

ROCK2 inhibitors for the treatment of chronic kidney disease

Day/Date:

Thursday, 25 October 2018

Location:

Poster Board #: TH-PO877

Time:

10:00 AM to 12:00 PM PDT

Session:

Diabetic Kidney Disease: Basic - I [PO0601-1]

Session Type:

Poster Presentation

 

The full abstract of the presentation can be found below and here: https://www.asn-online.org/education/kidneyweek/2018/program-abstract.aspx?controlId=3014989

 

BACKGROUND

 

The Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) serine/threonine kinases, ROCK1 and ROCK2, are central signalling proteins that regulate a range of cellular responses such as cell migration, contraction, proliferation, cytokine and growth factor expression, and integrin-mediated cell-to-cell adhesions. These processes are central to the aberrant wound healing response that can progress to chronic injury and organ fibrosis. Small molecule pan-ROCK inhibitors have been shown to be anti-fibrotic in a range of animal models including: bleomycin induced lung fibrosis, high fat diet induced liver fibrosis and models of kidney fibrosis. However, ROCK signalling is also involved in regulating vascular tone and pan-ROCK inhibitors have been shown to cause hyperaemia and hypotension, limiting their use in patients. There is significant homology between the ROCK1 and ROCK2 isoforms however there is evidence that ROCK2 has additional roles distinct from ROCK1 in both inflammation and wound healing. For example, ROCK2 is upregulated in diabetic kidney disease and in the diseased vascular network of patients at risk of chronic kidney disease (CKD).

 

METHODS

Redx have developed a series of potent ROCK2 inhibitors, that are highly selective against ROCK1 and a panel of 468 kinases.

 

RESULTS

Redx ROCK2 selective compounds potently suppress the release of pro-fibrotic factors from kidney mesangial cells, cultured in high glucose. In a model of acute kidney injury, our selective ROCK2 tool compound reduced podocyte damage, and the expression of inflammatory and profibrotic genes in the kidney.

 

In addition, in a telemetered rat study, no significant reduction in blood pressure or increase in heart rate was recorded, indicating that a selective ROCK2 inhibitor could avoid these side-effects typically observed with pan-ROCK inhibitors and increase the safety window at efficacious doses.

 

CONCLUSION

 

Highly selective ROCK2 inhibitors, therefore, could provide a novel and effective therapy for patients with progressive kidney fibrosis who currently have few and largely ineffective therapy options.

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

Andrew Saunders, Chief Medical Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc 

 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAEAFEFAAEPFAF

Redx Pharma Plc Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use